글로벌 심장 마커 테스트 시장 – 2031년까지의 산업 동향 및 예측

심장 마커 테스트 시장 분석 및 규모

심장 마커 검사의 맥락에서 위험 계층화는 트로포닌, CK-MB, B형 나트륨이뇨펩타이드(BNP)와 같은 바이오마커를 사용하여 환자의 미래 심혈관 사건 가능성을 평가하는 것을 말합니다. 이러한 마커의 수치가 높으면 심근 손상, 심장 스트레스 또는 기능 장애를 나타내므로 의료 서비스 제공자가 환자를 다른 위험 그룹으로 분류하는 데 도움이 됩니다. 이 계층화는 치료 결정을 안내하고 모니터링 강도를 결정하며 예후를 예측하여 환자의 심혈관 위험 프로필에 맞게 조정된 개인화된 관리 계획을 가능하게 합니다. 따라서 심장 마커 검사는 보다 공격적인 개입이나 보다 면밀한 모니터링을 통해 이익을 얻을 수 있는 고위험 환자를 식별하여 환자 결과를 최적화하는 데 중요한 역할을 합니다.

글로벌 심장 마커 검사 시장 규모는 2023년에 126억 8천만 달러로 평가되었으며, 2031년까지 254억 6천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 연평균 성장률은 9.10%입니다.

Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

보고 범위 및 시장 세분화       

시장 정의

심장 마커 검사는 심장이 손상되거나 스트레스를 받을 때 혈류로 방출되는 특정 물질을 측정하는 것을 포함합니다. 이러한 마커에는 크레아틴 키나제(CK-MB) 및 트로포닌(트로포닌 T 및 트로포닌 I)과 같은 효소와 미오글로빈 과 같은 단백질이 포함됩니다 . 이러한 마커의 수치가 높으면 심근 경색(심장 마비) 또는 기타 심장 손상과 같은 상태를 진단하는 데 도움이 됩니다. 심장 마커 검사는 조기 발견, 치료 효과 모니터링 및 임상 환경에서 심장 손상의 정도 평가에 필수적입니다.

심장 마커 테스트 시장 동향

운전자                                                                                          

• 노령 인구 증가

세계 인구의 고령화로 인해 심부전, 심근경색 및 기타 심장 질환과 같은 연령 관련 심혈관 질환의 유병률이 높아졌습니다. 노인은 이러한 질환에 더 취약하여 정기적인 모니터링과 심장 마커 검사를 통한 조기 발견이 필요합니다. 이러한 인구학적 변화는 심혈관 질환을 효과적으로 관리하고 치료하기 위한 진단 도구에 대한 수요를 증가시켜 심장 마커 검사 시장의 성장을 촉진합니다. 향상된 의료 인프라와 노인의 삶의 질 향상에 대한 강조는 고급 심장 진단 솔루션에 대한 필요성을 더욱 증가시킵니다.

• 진단 기술의 발전

Innovations such as high-sensitivity assays, automated analyzers, and point-of-care testing devices have greatly enhanced the accuracy, speed, and convenience of cardiac marker tests. These technological improvements allow for earlier and more precise detection of cardiac events, facilitating timely medical intervention and improving patient outcomes. Additionally, the integration of digital health solutions, such as smartphone-based diagnostics, is expanding access to cardiac marker testing, further propelling market growth. As technology continues to evolve, it is expected to drive continued advancements and adoption in cardiac marker testing worldwide.

Opportunities

• Increasing Strategic Collaborations

Collaborations between healthcare providers, diagnostic companies, and research institutions foster innovation and development of advanced cardiac marker tests. These collaborations enable the sharing of expertise, resources, and technology, leading to the creation of more sensitive and specific diagnostic tools. Joint ventures and alliances also facilitate faster regulatory approvals and market entry, expanding the availability of cutting-edge diagnostic solutions. Additionally, strategic collaborations often result in enhanced distribution networks and better access to emerging markets, ultimately driving the growth and adoption of cardiac marker testing worldwide.

• Expansion of Point-of-Care Testing (POCT)

POCT enables rapid, on-site diagnostic testing for cardiac markers, providing immediate results in various healthcare settings, including emergency departments, clinics, and even at patients' bedsides. This reduces the time to diagnosis and treatment for acute cardiac events, improving patient outcomes. The convenience and accessibility of POCT devices facilitate early detection and continuous monitoring of cardiovascular conditions. Advancements in POCT technology, combined with increasing adoption by healthcare providers, are propelling the growth of the cardiac marker testing market, ensuring timely and efficient cardiac care.

Restraints/Challenges

• High Initial Costs

Advanced diagnostic technologies and the reagents used for cardiac marker tests are often expensive, making these tests less affordable for many healthcare facilities, particularly in low- and middle-income countries. The initial investment in equipment and ongoing operational costs can be prohibitive, limiting widespread adoption. This cost barrier can prevent healthcare providers from implementing routine cardiac marker testing, reducing access to timely and accurate diagnostics for patients with cardiovascular conditions.  

• Lack of Skilled Professionals

Interpreting cardiac marker test results accurately requires specialized training and expertise, which many healthcare facilities, particularly in low-resource settings, may lack. This shortage of trained personnel can lead to misdiagnosis or delayed diagnosis, undermining the effectiveness of cardiac marker testing. Moreover, the complexity of some testing technologies necessitates proper handling and analysis to ensure reliable results.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In May 2022, Quidel Corporation launched the "Triage Cardiac Panel," FDA-approved for use in emergency departments to aid in diagnosing myocardial infarction. This panel specifically measures levels of creatine kinase MB, myoglobin, and troponin I, critical markers indicative of heart damage. The introduction of this diagnostic tool enhances rapid decision-making in emergency settings, facilitating quicker intervention and treatment for patients suspected of acute cardiac events
• In January 2022, PocDoc launched a revolutionary smartphone-based cardiovascular test aimed at pharmacies, private healthcare providers, and NHS facilities. This innovation covers a comprehensive five-market lipid panel, promising significant cost savings for the NHS through reduced staffing needs. This advancement aligns with the trend towards personalized diagnostics and decentralized healthcare solutions, potentially transforming how cardiovascular health is managed and monitored

Cardiac Marker Testing Market Scope

The market is segmented on the basis of type, product, disease and type of testing. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Type

• Troponin I and T
• Creatine kinase-MB (CK-MB)
• Brain Natriuretic peptide (Bnp or Nt-Probnp)
• Myoglobin
• HIGH-sensitivity C-reactive protein (hs-CRP)
• Other Biomarkers

Product

• Instruments
  • Chemiluminescence
  • Immunofluorescence
  • ELISA
  • Immunochromatography
• Reagents
• Kits

Disease

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome
• Atherosclerosis
• Ischemia

Type of Testing

• Laboratory Testing
  • Hospital Labs
  • Refrence Labs
  • Contract Labs
• Academic Institutions
• Point-Of-Care Testing

Cardiac Marker Testing Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, type, product, type of testing and disease as referenced above.      

The countries covered in the market report are the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of the Middle East and Africa (MEA), Brazil, Argentina and Rest of South America.   

North America dominates the market due to the region invests heavily in research and development, fostering innovation and technological advancement in diagnostic technologies. Major global players such asAbbott, Danaher, and others are headquartered in North America, ensuring a strong presence and extensive product availability. The region benefits from a well-established healthcare infrastructure, supporting widespread adoption of advanced diagnostic solutions.

Asia-Pacific is expected for rapid and lucrative growth in the market due to rising incidences of cardiovascular diseases. Public-private initiatives aimed at enhancing awareness among both patients and physicians about the importance of early diagnosis are driving this growth. Increasing healthcare expenditure and advancements in diagnostic technologies are further contributing to the region's expanding market for diagnostic solutions, making it a key area of focus for companies seeking growth opportunities in healthcare and diagnostics.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Cardiac Marker Testing Market Analysis

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 위에 제공된 데이터 포인트는 에피제네틱스 진단 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 활동하는 주요 기업은 다음과 같습니다.

• F. 호프만-라 로슈 유한회사(스위스)
• 애벗(미국)
• 지멘스(독일)
• 다나허(미국)
• bioMérieux, Inc. (프랑스)
• Ortho Clinical Diagnostics (미국)
• Randox Laboratories Ltd(영국)
• BG Medicine(미국)
• HUMAN Co (독일)
• Bhat Bio-tech India Private Limited(인도)
• 머크 KGaA(독일)
• 퍼킨엘머 주식회사(미국)
• QIAGEN(네덜란드)
• Agilent Technologies, Inc. (미국)
• 브루커(미국)
• Epigenomics AG(독일)
• MESO SCALE DIAGNOSTICS, LLC(미국)
• EKF Diagnostics Holdings plc. (영국)
• 넥서스-Dx(미국)
• LifeSign LLC. (미국)
• DIALAB GmbH(오스트리아)
• Beckman Coulter, Inc. (미국)

SKU-26277